Literature DB >> 1738186

Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines.

E S Marshall1, G J Finlay, J H Matthews, J H Shaw, J Nixon, B C Baguley.   

Abstract

BACKGROUND: The culture of cancer cells has many applications in chemosensitivity testing and new drug development.
PURPOSE: Our goal was to adapt simple semiautomated microculture methods for testing the chemosensitivity of melanoma cells freshly recovered from patients' tumors.
METHODS: Cells were cultured on a substrate of agarose and exposed continuously to cytotoxic drugs, the effects of which were measured by determining the uptake of [3H]thymidine 4-7 days later.
RESULTS: Immunocytochemical staining of cells cultured with 5-bromo-2'-deoxyuridine demonstrated that tumor cells were responsible for the measured thymidine incorporation. The effects of cytotoxic drugs were calculated as logarithmic 50% inhibitory concentrations and expressed as divergences from the mean in a log-mean graph. The inhibitory effects of amsacrine, etoposide, doxorubicin, cisplatin, mitomycin C, and fluorouracil were tested. Tumors differed widely in their sensitivity to these drugs, although sensitivity to the three topoisomerase-II-directed agents was highly correlated. Cells from two non-neoplastic hematopoietic progenitor cell lines (FT and 32D) showed chemosensitivity patterns distinct from those in the melanoma cells, indicating tissue selectivity. Two established melanoma cell lines, MM-96 and FME, were tested under the same conditions and showed sensitivity typical of at least some fresh specimens.
CONCLUSIONS: These results support the validity of melanoma cell lines as models of freshly resected melanoma cells. If successfully applied to other tumor types, such semiautomated approaches could find wide application in routine hospital laboratories for the chemosensitivity testing of patients' tumor cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1738186     DOI: 10.1093/jnci/84.5.340

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  13 in total

Review 1.  Topoisomerase I in multiple drug resistance.

Authors:  A Pessina
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

2.  In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.

Authors:  G J Finlay; E Marshall; J H Matthews; K D Paull; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide.

Authors:  B C Baguley; L Zhuang; E Marshall
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Topoisomerase I inhibitors and drug resistance.

Authors:  R E Parchment; A Pessina
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

5.  Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.

Authors:  Ji Eun Kim; Clare Stones; Wayne R Joseph; Euphemia Leung; Graeme J Finlay; Andrew N Shelling; Wayne A Phillips; Peter R Shepherd; Bruce C Baguley
Journal:  BMC Cancer       Date:  2012-04-04       Impact factor: 4.430

6.  Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.

Authors:  Clare J Stones; Ji Eun Kim; Wayne R Joseph; Euphemia Leung; Elaine S Marshall; Graeme J Finlay; Andrew N Shelling; Bruce C Baguley
Journal:  Front Genet       Date:  2013-05-08       Impact factor: 4.599

7.  A novel preclinical model of human malignant melanoma utilizing bioreactor rotating-wall vessels.

Authors:  L L Licato; V G Prieto; E A Grimm
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-03       Impact factor: 2.723

8.  Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee.

Authors:  C J Twelves; C Gardner; A Flavin; J Sludden; I Dennis; J de Bono; P Beale; P Vasey; C Hutchison; M A Macham; A Rodriguez; I Judson; N M Bleehen
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

9.  Heterogeneity of expression of epithelial-mesenchymal transition markers in melanocytes and melanoma cell lines.

Authors:  Ji Eun Kim; Euphemia Leung; Bruce C Baguley; Graeme J Finlay
Journal:  Front Genet       Date:  2013-05-31       Impact factor: 4.599

10.  Cell cycle times of short-term cultures of brain cancers as predictors of survival.

Authors:  C E Furneaux; E S Marshall; K Yeoh; S J Monteith; P J Mews; C A Sansur; R J Oskouian; K J Sharples; B C Baguley
Journal:  Br J Cancer       Date:  2008-10-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.